More men with newly diagnosed prostate cancer or suspected prostate cancer recurrence who underwent fluorocholine-18-PET/CT had high-impact clinical management changes, compared with those who received conventional imaging with technetium-99 whole-body bone scan and abdomen/pelvis CT scan, researchers reported at the Genitourinary Cancers Symposium. The findings also showed that those in the FCH-PET/CT group had more frequent management changes, but the difference wasn't statistically significant.
Fluorocholine-18-PET/CT may top traditional prostate cancer imaging
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.